{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:59:43Z","timestamp":1793393983992,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.bioorg.2021.105565","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T01:42:44Z","timestamp":1639618964000},"page":"105565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Discovery of 7-alkyloxy- [1,2,4] triazolo[1,5-a] pyrimidine derivatives as selective positive modulators of GABAA1 and GABAA4 receptors with potent antiepileptic activity"],"prefix":"10.1016","volume":"119","author":[{"given":"Jun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxi","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longjiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2021.105565_b0005","doi-asserted-by":"crossref","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105565_b0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/WCO.0b013e3283507e73","article-title":"Evidence-based review on the natural history of the epilepsies","volume":"25","author":"Schmidt","year":"2012","journal-title":"Curr. Opin. Neurol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105565_b0015","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/pr.120.019539","article-title":"Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options","volume":"72","author":"L\u00f6scher","year":"2020","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105565_b0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1124\/pr.108.00505","article-title":"Subtypes of gamma-aminobutyric acid (A) receptors: classification on the basis of subunit composition, pharmacology, and function","volume":"60","author":"Olsen","year":"2008","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105565_b0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuron.2011.12.012","article-title":"Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease","volume":"73","author":"Brickley","year":"2012","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.bioorg.2021.105565_b0030","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0021-9258(18)45961-3","article-title":"A single histidine in GABAA receptors is essential for benzodiazepine agonist binding","volume":"267","author":"Wieland","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105565_b0035","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1523\/JNEUROSCI.3426-07.2008","article-title":"Subunit-specific trafficking of GABA(A) receptors during status epilepticus","volume":"28","author":"Goodkin","year":"2008","journal-title":"J. Neurosci.: Off. J. Soc. Neurosci."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105565_b0040","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ana.410380609","article-title":"Experimental status epilepticus alters \u03b3-aminobutyric acid type A receptor function in CA1 pyramidal neurons","volume":"38","author":"Kapur","year":"1995","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105565_b0045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1152\/jn.1989.61.2.417","article-title":"Evidence that repetitive seizures in the hippocampus cause a lasting reduction of GABAergic inhibition","volume":"61","author":"Kapur","year":"1989","journal-title":"J. Neurophysiol."},{"issue":"Suppl. 8","key":"10.1016\/j.bioorg.2021.105565_b0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12025","article-title":"How theories evolved concerning the mechanism of action of barbiturates","volume":"53","author":"L\u00f6scher","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.bioorg.2021.105565_b0055","doi-asserted-by":"crossref","unstructured":"G. Martinez Botella, F.G. Salituro, B.L. Harrison, R.T. Beresis, Z. Bai, K. Shen, G.M. Belfort, C.M. Loya, M.A. Ackley, S.J. Grossman, E. Hoffmann, S. Jia, J. Wang, J.J. Doherty, A.J. Robichaud, Neuroactive Steroids. 1. Positive Allosteric Modulators of the (gamma-Aminobutyric Acid)A Receptor: Structure-Activity Relationships of Heterocyclic Substitution at C-21, J. Med. Chem. 58(8) (2015) 3500-3511. doi:10.1021\/acs.jmedchem.5b00032.","DOI":"10.1021\/acs.jmedchem.5b00032"},{"issue":"Suppl. 6","key":"10.1016\/j.bioorg.2021.105565_b0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/epi.12289","article-title":"Neuroactive steroids for the treatment of status epilepticus","volume":"54","author":"Rogawski","year":"2013","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105565_b0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1476-5381.2010.01059.x","article-title":"Tolerance to allopregnanolone with focus on the GABA-A receptor","volume":"162","author":"Turkmen","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2021.105565_b0070","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ejmech.2016.01.009","article-title":"The importance of triazole scaffold in the development of anticonvulsant agents","volume":"109","author":"Ayati","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105565_b0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bioorg.2018.03.001","article-title":"Design, synthesis, in vivo and in silico evaluation of phenacyl triazole hydrazones as new anticonvulsant agents","volume":"78","author":"Dehestani","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105565_b0080","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejmech.2016.08.032","article-title":"New (arylalkyl)azole derivatives showing anticonvulsant effects could have VGSC and\/or GABA(A)R affinity according to molecular modeling studies","volume":"124","author":"Sari","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105565_b0085","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.bmc.2014.12.016","article-title":"Novel agonists of benzodiazepine receptors: design, synthesis, binding assay and pharmacological evaluation of 1,2,4-triazolo[1,5-a]pyrimidinone and 3-amino-1,2,4-triazole derivatives","volume":"23","author":"Faizi","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105565_b0090","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3109\/14756366.2013.776555","article-title":"Synthesis and evaluation of the anticonvulsant activity of 8-alkoxy-4,5-dihydrobenzo[b][1,2,4]triazolo[4,3-d][1,4]thiazepine derivatives","volume":"29","author":"Deng","year":"2014","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105565_b0095","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ejmech.2014.09.034","article-title":"Studies on the anticonvulsant activity of 4-alkyl-1,2,4-triazole-3-thiones and their effect on GABAergic system","volume":"86","author":"Plech","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105565_b0100","doi-asserted-by":"crossref","first-page":"111824","DOI":"10.1016\/j.ejmech.2019.111824","article-title":"Discovery of [1,2,4]-triazolo [1,5-a]pyrimidine-7(4H)-one derivatives as positive modulators of GABA(A1) receptor with potent anticonvulsant activity and low toxicity","volume":"185","author":"Huang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2021.105565_b0105","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1080\/10286020.2018.1529030","article-title":"Synthesis and in vitro anti-epileptic activities of novel [1,2,4]-triazolo[1,5-a]pyrimidin-7(4H)-one derivatives","volume":"21","author":"Ding","year":"2019","journal-title":"J. Asian Nat. Prod. Res."},{"key":"10.1016\/j.bioorg.2021.105565_b0110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejmech.2012.11.026","article-title":"Synthesis, characterization and preliminary anticonvulsant evaluation of some 4-alkyl-1,2,4-triazoles","volume":"60","author":"Plech","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"S1","key":"10.1016\/j.bioorg.2021.105565_b0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.bioorg.2021.105565_b0120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejmech.2013.04.019","article-title":"Augmentation of GABAergic neurotransmission by novel N-(substituted)-2-[4-(substituted)benzylidene]hydrazinecarbothioamides-a potential anticonvulsant approach","volume":"64","author":"Tripathi","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105565_b0125","doi-asserted-by":"crossref","unstructured":"Y. Yamamoto, Y. Watanabe, S. Ohnishi, 1, 3-Oxazines and Related Compounds. XIII. Reaction of Acyl Meldrum's Acids with Schiff Bases Giving 2, 3-Disubstituted 5-Acy1-3, 4, 5, 6-tetrahydro-2<I>H<\/I>-1, 3-oxazine-4, 6-diones and 2, 3, 6-Trisubstituted 2, 3-Dihydro-1, 3-oxazin-4-ones, CHEMICAL & PHARMACEUTICAL BULLETIN 35(5) (1987) 1860-1870. doi:10.1248\/cpb.35.1860.","DOI":"10.1248\/cpb.35.1860"},{"issue":"Suppl. 7","key":"10.1016\/j.bioorg.2021.105565_b0130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1528-1157.44.s7.10.x","article-title":"Preclinical development of antiepileptic drugs: past, present, and future directions","volume":"44","author":"White","year":"2003","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.bioorg.2021.105565_b0135","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s11064-017-2222-z","article-title":"Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs","volume":"42","author":"L\u00f6scher","year":"2017","journal-title":"Neurochem. Res."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105565_b0140","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2021.105565_b0145","first-page":"713","article-title":"Anticonvulsant drugs: mechanisms of action","volume":"44","author":"Macdonald","year":"1986","journal-title":"Adv. Neurol."},{"issue":"9","key":"10.1016\/j.bioorg.2021.105565_b0150","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s11064-020-03052-9","article-title":"HAP1 modulates epileptic seizures by regulating GABAAR function in patients with temporal lobe epilepsy and in the PTZ-induced epileptic model","volume":"45","author":"Li","year":"2020","journal-title":"Neurochem. Res."},{"issue":"11","key":"10.1016\/j.bioorg.2021.105565_b0155","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1080\/00207454.2018.1481064","article-title":"Neuropathological profile of the pentylenetetrazol (PTZ) kindling model","volume":"128","author":"Samokhina","year":"2018","journal-title":"Int. J. Neurosci."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105565_b0160","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1080\/14756366.2019.1651722","article-title":"Design, synthesis and biological evaluation of N-substituted alpha-hydroxyimides and 1,2,3-oxathiazolidine-4-one-2,2-dioxides with anticonvulsant activity","volume":"34","author":"Sabatier","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2021.105565_b0165","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7150\/ijms.20001","article-title":"Molecular mechanism of action and safety of 5-(3-chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione - a novel anticonvulsant drug candidate","volume":"14","author":"Kapro\u0144","year":"2017","journal-title":"Int. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105565_b0170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.nurt.2006.11.010","article-title":"Molecular targets for antiepileptic drug development","volume":"4","author":"Meldrum","year":"2007","journal-title":"Neurotherapeutics: J. Am. Soc. Experimental NeuroTherapeutics"},{"issue":"8","key":"10.1016\/j.bioorg.2021.105565_b0175","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.seizure.2013.04.015","article-title":"Molecular mechanisms of antiseizure drug activity at GABAA receptors","volume":"22","author":"Greenfield","year":"2013","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105565_b0180","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0301-0082(02)00013-8","article-title":"Drug interactions at GABAA receptors","volume":"67","author":"Korpi","year":"2002","journal-title":"Prog. Neurobiol."},{"issue":"9","key":"10.1016\/j.bioorg.2021.105565_b0185","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrd3502","article-title":"Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes","volume":"10","author":"Rudolph","year":"2011","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"12","key":"10.1016\/j.bioorg.2021.105565_b0190","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/81800","article-title":"Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms","volume":"3","author":"Walters","year":"2000","journal-title":"Nat. Neurosci."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105565_b0195","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1528-1167.2006.00497.x","article-title":"Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels","volume":"47","author":"Quilichini","year":"2006","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105565_b0200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1085\/jgp.200810081","article-title":"Pentobarbital produces activation and block of {alpha}1{beta}2{gamma}2S GABAA receptors in rapidly perfused whole cells and membrane patches: divergent results can be explained by pharmacokinetics","volume":"133","author":"Gingrich","year":"2009","journal-title":"J. Gen. Physiol."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105565_b0205","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.seizure.2010.10.027","article-title":"Antiepileptic drug therapy the story so far","volume":"19","author":"Brodie","year":"2010","journal-title":"Seizure"},{"key":"#cr-split#-10.1016\/j.bioorg.2021.105565_b0210.1","doi-asserted-by":"crossref","unstructured":"D. Vohora, P. Saraogi, M.A. Yazdani, M. Bhowmik, R. Khanam, K.K. Pillai, Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs, Drugs of today (Barcelona, Spain : 1998) 46","DOI":"10.1358\/dot.2010.46.4.1445795"},{"key":"#cr-split#-10.1016\/j.bioorg.2021.105565_b0210.2","doi-asserted-by":"crossref","unstructured":"(4) (2010) 265-77. doi:10.1358\/dot.2010.46.4.1445795.","DOI":"10.1358\/dot.2010.46.4.1445795"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105565_b0215","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0920-1211(92)90040-Z","article-title":"Excitatory amino acids in epilepsy and potential novel therapies","volume":"12","author":"Meldrum","year":"1992","journal-title":"Epilepsy Res."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105565_b0220","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.3390\/molecules17078285","article-title":"New trifluoromethyl triazolopyrimidines as anti-Plasmodium falciparum agents","volume":"17","author":"Boechat","year":"2012","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"7","key":"10.1016\/j.bioorg.2021.105565_b0225","doi-asserted-by":"crossref","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","article-title":"The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bioorg.2021.105565_b0230","unstructured":"A. National Research Council Committee for the Update of the Guide for the Care Use of Laboratory, The National Academies Collection: Reports funded by National Institutes of Health, Guide for the Care and Use of Laboratory Animals, National Academies Press (US), Washington (DC), 2011."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105565_b0235","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3949\/ccjm.51.2.293","article-title":"Antiepileptic Drug Development Program","volume":"51","author":"Porter","year":"1984","journal-title":"Cleveland Clinic quarterly"},{"key":"10.1016\/j.bioorg.2021.105565_b0240","doi-asserted-by":"crossref","unstructured":"H. Ucar, K. Van derpoorten, S. Cacciaguerra, S. Spampinato, J.P. Stables, P. Depovere, M. Isa, B. Masereel, J. Delarge, J.H. Poupaert, Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives, J. Med. Chem. 41(16) (1998) 3102. doi: 10.1021\/jm980341b.","DOI":"10.1021\/jm980259g"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821009433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821009433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:26:20Z","timestamp":1758615980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821009433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":49,"alternative-id":["S0045206821009433"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105565","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 7-alkyloxy- [1,2,4] triazolo[1,5-a] pyrimidine derivatives as selective positive modulators of GABAA1 and GABAA4 receptors with potent antiepileptic activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105565"}}